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Abstract
A 57-year-old woman with a previous history of aesthetic surgery for breast reduction presented with a subcutaneous mass in the right 
axilla. A CT scan showed a solid mass on the chest wall, and she underwent surgical resection with a diagnosis of aggressive fibromatosis. 
After a 10-month period of follow-up, a local recurrence occurred, and in accordance with the up-to-date approach, the recurrence has been 
treated with a conservative approach (medical treatments) with good control of the symptoms and downsizing of the lesion.
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Introduction
Aggressive fibromatosis (AF), also known as desmoid tumour or musculoaponeurotic fibromatosis, is a monoclonal fibroblastic proliferative 
disease [1]. The tumours are composed of spindle-shaped cells placed in a collagenous matrix without alterations, which is typical of 
malignancy. AF grows slowly and never metastasises; however, local recurrence and adjacent organ involvement are important causes of 
morbidity and mortality.
Available treatments include surgery, radiotherapy, systemic medical treatment, hormone therapy, anti-inflammatory drugs, and tyrosine 
kinase inhibitors. Recently, it has been demonstrated that an initial aggressive approach (surgery and/or radiotherapy) might overtreat 
50% of the patients [2].
Case
A 57-year-old woman with a previous history of aesthetic surgery for breast reduction presented with a subcutaneous mass in the right 
axilla. The patient underwent a computed tomography (CT) scan, showing a contrast-enhanced solid mass in the right axilla, with a total 
extra-pleural growth (Figure 1). A positron emission tomography (PET)-CT scan (Figure 2), showed an intense Fludeoxyglucose (FDG) 
uptake of the lesion, and a subsequent ultrasound (US)-guided biopsy disclosed mesenchymal tumour with uncertain malignant potential.
The patient underwent a wide soft-tissue surgical resection including major and minor pectoralis muscles, partial resection of the serratus 
anterior, and of the right breast upper external quadrant. The macroscopic pathological report described a white mass with a hard consistency 
and irregular margins, and the final histological diagnosis was extra-abdominal AF, with free resection margins, and an immune-phenotype 
positive for beta-catenin.
A follow-up CT scan performed 10 months after surgery disclosed local recurrence infiltrating the intercostal muscles, the pleura, and the 
pectoralis muscles (Figure 3). Subsequent MRI (Figure 4) demonstrated a 10 x 3.5 cm recurrence of AF, confirmed by the US-guided 
biopsy.
Based on the new strategies of approach, a treatment based on the use of tamoxifen and anti-inflammatory drugs, along with a gastric pro-
tection, was indicated for the patient. The therapy prescribed included tamoxifen 20 mg/diem and celecoxib 200 mg/diem (anti-inflammatory 
COX-2 inhibitor), with good control of the symptoms and (initial) downsizing of the lesion after 12 months of treatment, as demonstrated by 
CT scan (Figure 5).
Figure 1. The axial CT scan at first diagnosis, showing a contrast-enhanced solid mass (arrow) in the right axilla, with a total extrapleural growth.
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Figure 2. An axial fused PET-CT image shows an intense FDG uptake of the same lesion showed in Figure 1.
Figure 3. An axial CT scan at recurrence, showing a contrast-enhanced solid tissue (arrow) along the right chest wall, infiltrating the intercostal 
muscles and the pectoralis muscles, demonstrated at biopsy as recurrence of AF.
Discussion
AF (or desmoid tumour) is an uncommon mesenchymal tumour with a fibrotic band-like consistency, characterised by excessive proliferation 
of fibroblast-like cells [2].
The incidence of fibromatosis in the general population is 2–4 cases/million per year, with a slight female preponderance and peak incidences 
in the 3rd-4th decades of life [2]. AF is a locally aggressive tumour with no tendency to metastasise. However, local recurrence and adjacent 
organ involvement are important causes of morbidity and mortality.
The causes of AF are still unclear but have been related to trauma, hormonal factors, and genetic associations [such as adenomatous 
polyposis and mutations of the adenomatous polyposis coli (APC)  gene] [3]. 
AF can be intra-abdominal or extra-abdominal, being located in the chest wall 8–10% of all the extra-abdominal sites [4]. 
Before 2000, radical surgical resection was considered to be the standard treatment because complete excision with negative margins was 
considered to be the primary goal, such as indicated for sarcomas.
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Figure 4. Coronal post-Gd MR T1 weighted image with fat suppression, showing the presence of an irregular enhancing solid tissue along the 
right chest wall (arrows), infiltrating the adjacent pleura and lung.
Figure 5. An axial CT scan, after 12 months of treatment, showing an initial downsizing of the lesion, contoured by a white line.
However, nowadays, amputation is no longer considered the most appropriate treatment in locally advanced AF, because the consequences 
of radical excision can be worse than the disease itself. Moreover, the fact that some tumours recur after surgery, but then remain stable 
without treatment, suggests that growth factors released following surgery may promote recurrence in tumours that would be otherwise 
indolent. 
A recently proposed treatment algorithm for AF [2] begins with a careful clinical assessment and a two-month follow-up, in order to discriminate 
between rapidly enlarging and indolent tumours, so that more aggressive therapies may be reserved for those who really need it.
Valid current alternative treatments to surgery and radiotherapy are the anti-oestrogen and anthracycline-containing regimen [5] of 
tamoxifen, anti-inflammatory drugs (such as sulindac, celecoxib, and indomethacin), tyrosine kinase inhibitors (such as imatinib [6]), 
and cryoablation [2].
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In our case, surgical resection was performed because of unclear histology at biopsy; at the time of local recurrence, re-do surgery was 
avoided, and according to the reported advances in knowledge of therapies for AF, the patient has been treated with tamoxifen and celecoxib. 
We saw initial promising results with control of pain and partial reduction of the lesion after 12 months of treatment.
Conclusion
In conclusion, the current treatment for AF should include medical treatments alternative to surgery and radiotherapy, as they are able to 
ensure good control of symptoms and reduce the possibility of postoperative complications.
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